Evidence map›Paper›PMID 25710376›Full record

ArticlePloS one2015

Active immunization with an octa-valent Staphylococcus aureus antigen mixture in models of S. aureus bacteremia and skin infection in mice.

Sanne van den Berg, Dennis G A M Koedijk, Jaap Willem Back, Jolanda Neef, Annette Dreisbach, Jan Maarten van Dijl, Irma A J M Bakker-Woudenberg, Girbe Buist

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. AViruses · 2020
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Prevention and treatment of Staphylococcus aureus biofilms.Expert review of anti-infective therapy · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Sanne van den BergDepartment of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, Rotterdam, the Netherlands.
Dennis G A M KoedijkDepartment of Medical Microbiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Jaap Willem BackPepscan Therapeutics BV, Lelystad, the Netherlands.
Jolanda NeefDepartment of Medical Microbiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Annette DreisbachDepartment of Medical Microbiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Jan Maarten van DijlDepartment of Medical Microbiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Irma A J M Bakker-WoudenbergDepartment of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, Rotterdam, the Netherlands.
Girbe BuistDepartment of Medical Microbiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
University Medical Center Groningen · NLErasmus MC · NLPepscan (Netherlands) · NLUniversity of Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proteomic studies with different Staphylococcus aureus isolates have shown that the cell surface-exposed and secreted proteins IsaA, LytM, Nuc, the propeptide of Atl (pro-Atl) and four phenol-soluble modulins α (PSMα) are invariantly produced by this pathogen. Therefore the present study was aimed at investigating whether these proteins can be used for active immunization against S. aureus infection in mouse models of bacteremia and skin infection. To this end, recombinant His-tagged fusions of IsaA, LytM, Nuc and pro-Atl were isolated from Lactococcus lactis or Escherichia coli, while the PSMα1-4 peptides were chemically synthesized. Importantly, patients colonized by S. aureus showed significant immunoglobulin G (IgG) responses against all eight antigens. BALB/cBYJ mice were immunized subcutaneously with a mixture of the antigens at day one (5 μg each), and boosted twice (25 μg of each antigen) with 28 days interval. This resulted in high IgG responses against all antigens although the response against pro-Atl was around one log lower compared to the other antigens. Compared to placebo-immunized mice, immunization with the octa-valent antigen mixture did not reduce the S. aureus isolate P load in blood, lungs, spleen, liver, and kidneys in a bacteremia model in which the animals were challenged for 14 days with a primary load of 3 × 10(5) CFU. Discomfort scores and animal survival rates over 14 days did not differ between immunized mice and placebo-immunized mice upon bacteremia with S. aureus USA300 (6 × 10(5) CFU). In addition, this immunization did not reduce the S. aureus isolate P load in mice with skin infection. These results show that the target antigens are immunogenic in both humans and mice, but in the used animal models do not result in protection against S. aureus infection.

Indexed as

AnimalsAntigens, BacterialBacteremiaBacterial ProteinsBacterial ToxinsEndopeptidasesImmunoglobulin GMiceMice, Inbred BALB CMicrococcal NucleaseSkin Diseases, InfectiousStaphylococcal InfectionsStaphylococcal VaccinesVaccinationAntigens, BacterialBacterial ProteinsBacterial ToxinsEndopeptidasesImmunoglobulin GIsaA antigen, staphylococcusLytM protein, Staphylococcus aureusMicrococcal Nucleasenuc protein, staphylococcusstaphylococcal delta toxinStaphylococcal Vaccines

Identifiers

PMID25710376
PMCPMC4339199
OpenAlexW2107114776

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.